ASX ANNOUNCEMENTS

Array ( [2018] => Array ( [April] => Array ( [0] => 1716 [1] => 1714 [2] => 1706 [3] => 1690 ) [March] => Array ( [0] => 1677 [1] => 1697 [2] => 1648 ) [February] => Array ( [0] => 1625 [1] => 1615 [2] => 1607 ) [January] => Array ( [0] => 1598 [1] => 1590 [2] => 1583 [3] => 1581 [4] => 1579 [5] => 1577 [6] => 1567 ) ) [2017] => Array ( [December] => Array ( [0] => 1564 [1] => 1562 [2] => 1559 [3] => 1552 [4] => 1549 [5] => 1542 [6] => 1540 [7] => 1537 [8] => 1523 [9] => 1521 [10] => 1519 [11] => 1508 [12] => 1506 [13] => 1504 ) [November] => Array ( [0] => 1502 [1] => 1500 [2] => 1498 [3] => 1496 [4] => 1494 [5] => 1491 [6] => 1488 [7] => 1484 [8] => 1466 ) [October] => Array ( [0] => 1460 [1] => 1445 [2] => 1443 [3] => 1441 [4] => 1438 [5] => 1414 [6] => 1407 ) [September] => Array ( [0] => 1377 [1] => 1353 ) [August] => Array ( [0] => 1337 [1] => 1339 [2] => 1329 [3] => 1326 [4] => 1324 ) [July] => Array ( [0] => 1290 [1] => 1286 [2] => 1282 [3] => 1259 [4] => 1235 ) [June] => Array ( [0] => 1094 [1] => 957 [2] => 317 ) [May] => Array ( [0] => 220 [1] => 225 [2] => 224 ) [April] => Array ( [0] => 226 [1] => 228 [2] => 323 [3] => 325 ) [March] => Array ( [0] => 327 [1] => 329 [2] => 332 [3] => 334 [4] => 336 [5] => 338 [6] => 340 [7] => 342 ) [February] => Array ( [0] => 344 [1] => 346 [2] => 348 [3] => 350 ) [January] => Array ( [0] => 352 [1] => 354 [2] => 356 [3] => 358 ) ) [2016] => Array ( [December] => Array ( [0] => 372 [1] => 374 ) [November] => Array ( [0] => 377 [1] => 379 [2] => 381 [3] => 383 [4] => 385 ) [October] => Array ( [0] => 387 [1] => 391 [2] => 389 [3] => 393 [4] => 395 [5] => 397 ) [September] => Array ( [0] => 399 [1] => 401 [2] => 403 ) [August] => Array ( [0] => 405 [1] => 407 [2] => 409 [3] => 411 ) [July] => Array ( [0] => 427 [1] => 433 [2] => 434 [3] => 435 [4] => 436 ) [June] => Array ( [0] => 437 [1] => 440 ) [May] => Array ( [0] => 441 [1] => 446 [2] => 448 [3] => 449 ) [April] => Array ( [0] => 600 ) [March] => Array ( [0] => 454 [1] => 455 ) [February] => Array ( [0] => 456 [1] => 460 ) [January] => Array ( [0] => 1295 [1] => 461 ) ) [2015] => Array ( [December] => Array ( [0] => 462 ) [November] => Array ( [0] => 470 [1] => 468 [2] => 469 [3] => 471 [4] => 472 ) [October] => Array ( [0] => 473 [1] => 478 [2] => 479 [3] => 480 ) [September] => Array ( [0] => 481 [1] => 486 [2] => 487 ) [August] => Array ( [0] => 489 [1] => 488 [2] => 490 [3] => 491 [4] => 492 [5] => 493 [6] => 494 ) [July] => Array ( [0] => 495 [1] => 498 ) [June] => Array ( [0] => 499 [1] => 500 ) [May] => Array ( [0] => 501 [1] => 509 [2] => 510 [3] => 511 [4] => 512 [5] => 513 [6] => 514 [7] => 515 [8] => 524 [9] => 525 [10] => 526 [11] => 527 [12] => 528 [13] => 529 [14] => 530 ) [April] => Array ( [0] => 531 [1] => 538 [2] => 539 [3] => 540 [4] => 541 [5] => 542 [6] => 543 [7] => 545 [8] => 548 [9] => 550 [10] => 551 [11] => 555 [12] => 556 ) [March] => Array ( [0] => 557 [1] => 562 [2] => 563 [3] => 564 ) [February] => Array ( [0] => 565 [1] => 567 [2] => 573 [3] => 574 [4] => 575 [5] => 576 ) [January] => Array ( [0] => 577 [1] => 582 [2] => 583 [3] => 584 ) ) [2014] => Array ( [December] => Array ( [0] => 360 [1] => 362 [2] => 364 [3] => 366 [4] => 368 [5] => 370 ) ) )

December

21.12.2017 Change of Directors Interest Notice x 3
21.12.2017 Appendix 3B
18.12.2017 Notice of General Meeting/Proxy Form
14.12.2017 Completion of Cancellation of Unvested Loan Shares
13.12.2017 Change in substantial holding
08.12.2017 Cleansing Notice
08.12.2017 Appendix 3B-Placement
07.12.2017 Letter to Ineligible Shareholders
01.12.2017 Letter to Optionholders
01.12.2017 Appendix 3B
01.12.2017 Prospectus
01.12.2017 Appendix 3X – Dr Morstyn
01.12.2017 Appendix 3B
01.12.2017 Amgen Pioneer Dr George Morstyn Joins Actinogen Board

November

29.11.2017 Results of Annual General & Special General Meetings
29.11.2017 Early Efficacy & Safety Data Planned for XanADu Trial
29.11.2017 Placement Fully Funds Completion of XanADu Alzheimer’s Trial
29.11.2017 Managing Director’s Annual General Meeting Presentation
29.11.2017 Chairman’s Annual General Meeting Address
27.11.2017 Trading Halt Request
22.11.2017 Leading Alzheimer’s Researchers to Address Shareholders
15.11.2017 R&D Rebate Received Totalling $1.22 Million
02.11.2017 Amgen Pioneer to Join Actinogen Board

October

30.10.2017 Quarterly Update & Appendix 4C
23.10.2017 Annual Report to Shareholders
23.10.2017 Notice of Special General Meeting & Proxy Form
23.10.2017 Notice of Annual General Meeting/Proxy Form
17.10.2017 Actinogen to be showcased at key conferences
12.10.2017 Investor Newsletter
11.10.2017 Final Major Market Patent Granted for Xanamem

September

22.09.2017 Lapse of Unlisted Options
07.09.2017 First patient completes landmark Alzheimer’s disease trial

August

18.08.2017 Appendix 4E & Financial Statements
18.08.2017 Appendix 4G
16.08.2017 First UK patient treated in ground-breaking Alzheimer’s clinical trial
14.08.2017 Final Director’s Interest Notice
14.08.2017 Resignation of Director

July

26.07.2017 June Quarterly Update
19.07.2017 Actinogen Presenting at Bioshares Biotech 2017 Summit
12.07.2017 Appendix 3B – Issue of Employee Options
07.07.2017 Appendix 3Y – Change of Director’s Interest Notice
03.07.2017 Lapse of Unlisted Options

June

22.06.2017 First US patients treated in landmark Alzheimer’s disease trial
19.06.2017 Actinogen Medical attending BIO 2017
01.06.2017 First UK site goes live in global Alzheimer’s disease Clinical Trial

May

16.05.2017 First patient treated in landmark Alzheimer’s disease clinical trial
09.05.2017 Appendix 3B – Exercise of Options
09.05.2017 Section 708A Notice

April

26.04.2017 Becoming a substantial holder
26.04.2017 Section 708A Notice
26.04.2017 Appendix 3B – Exercise of Options
26.04.2017 March Quarterly Update

March

29.03.2017 Appendix 3Y – Change of Director’s Interest Notice
27.03.2017 Latest Investor Presentation
27.03.2017 Appendix 3Y – Change of Director’s Interest Notice
27.03.2017 Appendix 3B
16.03.2017 Quarterly Investor Newsletter
08.03.2017 TGA Regulatory Approval for Alzheimer’s Phase II Trial
01.03.2017 Appendix 3X – Initial Director’s Interest Notice
01.03.2017 Actinogen Medical Appoints Dr Geoff Brooke as Chairman

February

27.02.2017 Actinogen Medical Financial Results
10.02.2017 UK Regulatory Approval for Alzheimer’s Disease Clinical Trial – XanADu
09.02.2017 Xanamem research published in prestigious medical journal
06.02.2017 Issue of Employee & Advisor Options

January

23.01.2017 Appendix 4C – Quarterly
09.01.2017 Ceasing to be a substantial holder
03.01.2017 Lapse of Unlisted Options
03.01.2017 FDA Approval to Commence Alzheimer’s Disease Clinical Trial

December

19.12.2016 Significant Advance in Development of Alzheimer’s Drug
06.12.2016 Xanamem Research Presented at CTAD

November

30.11.2016 Results of Annual General Meeting
30.11.2016 Retirement of Martin Rogers as Chairman of Actinogen Medical
30.11.2016 Appendix 3Z
30.11.2016 Chairman’s AGM Address
30.11.2016 CEO’s Presentation to AGM

October

26.10.2016 Appendix 4C – Quarterly
24.10.2016 Annual Report to Shareholders
24.10.2016 Notice of Annual General Meeting / Proxy Form
14.10.2016 Ceasing to be a Substantial Holder
06.10.2016 Ceasing to be a Substantial Holder
05.10.2016 Changes to the Actinogen Medical Board

September

29.09.2016 FDA Feedback on Xanamem Alzheimer’s Trial
05.09.2016 R&D Tax Rebate
01.09.2016 Investor Update – August 2016

August

31.08.2016 Appendix 4G
31.08.2016 Appendix 4E & Financial Statements
24.08.2016 Ceasing to be a Substantial Shareholder
17.08.2016 Less Than Marketable Parcel Sale

July

28.07.2016 Landmark Research on Excess Cortisol & Alzheimer’s Disease
20.07.2016 US Patent Granted – Further Extends Xanamem Protection
15.07.2016 US Roadshow Investor Presentation
15.07.2016 Appendix 4C Quarterly
08.07.2016 Issue of Employee Options

June

29.06.2016 Xanamem and AIBL Data Showcase Cortisol Hypothesis in Alzheimer’s Disease
08.06.2016 US FDA Feedback Enhances Alzheimer’s Study

May

20.05.2016 Change of Share Register Notification
06.05.2016 Section 708A Notice
06.05.2016 Appendix 3B
03.05.2016 BioEquity & AusBiotech Asia Investor Presentation May 2016

April

15.04.2016 Appendix 4C – Quarterly

March

22.03.2016 Launch of XanADu Phase II Clinical Trial
10.03.2016 Xanamem Cortisol Hypothesis Investor Presentation

February

19.02.2016 Appendix 4D & Half Year Report
09.02.2016 R&D Tax Rebate

January

27.01.2016 Appendix 4C – Quarterly
04.01.2016 Appendix 3Y – Dr Bill Ketelbey

December

01.12.2015 Investor Update – December 2015

November

17.11.2015 Change of Company Name
12.11.2015 Results of AGM
12.11.2015 CEO’s AGM Presentation
12.11.2015 Chairman’s AGM Address
06.11.2015 Release of Securities from Voluntary Escrow

October

15.10.2015 Appendix 4C – Quarterly
07.10.2015 Understanding Alzheimer’s Symposium
07.10.2015 Annual Report to Shareholders
07.10.2015 Notice of Annual General Meeting and Proxy Form

September

30.09.2015 Expiry of Listed Options
29.09.2015 Positive Trial Results for Alzheimer’s Drug Xanamem
28.09.2015 Trading Halt

August

31.08.2015 Appendix 4G
31.08.2015 Expiry of Listed Options & Waiver of Listing Rule 6.24
31.08.2015 Appendix 4E & Financial Statements
17.08.2015 Investor Update August 2015
12.08.2015 Employee Share Plan Vesting Conditions Met
11.08.2015 Employee Share Plan Vesting Conditions Met
11.08.2015 Clinical Trial Successfully Completed with Xanamem

July

16.07.2015 Appendix 4C – Quarterly
07.07.2015 Investor Roadshow Presentation

June

26.06.2015 Change of Address & Executive Chairman Agreement
11.06.2015 Excellent Research Progress with Promising Alzheimer’s Drug

May

21.05.2015 Employee Share Plan Vesting Conditions Met
21.05.2015 ASX Spotlight Series Singapore/Hong Kong May 2015
20.05.2015 Appendix 3B
20.05.2015 Appendix 3Y: Dr Anton Uvarov
20.05.2015 Appendix 3Y: Dr Bill Ketelbey
20.05.2015 Appendix 3Y: Dr Jason Loveridge
20.05.2015 Appendix 3Y: Martin Rogers
14.05.2015 Notice of Change of Interests of Substantial Holder
12.05.2015 Successful Completion of First Stage of Alzheimer’s Drug Trial
07.05.2015 Change in Substantial Holding
07.05.2015 Ceasing to be a Substantial Holder
06.05.2015 Information Required Under Listing Rule 3.10.5A
06.05.2015 Section 708A Notice
06.05.2015 Appendix 3B
01.05.2015 Notice Under ASIC Class Order (CO 09-425)

April

30.04.2015 Share Purchase Plan
28.04.2015 Change in Substantial Shareholding
27.04.2015 Change in Substantial Shareholding x 2
24.04.2015 Ethics Approval Granted for Second Stage of Phase I Study
24.04.2015 Successful Capital Raising to Support Alzheimer’s Research
24.04.2015 Appendix 4C: Quarterly
22.04.2015 Trading Halt
16.04.2015 Further Clinical Trial Update on Xanamem
16.04.2015 Xanamem Clinical Advisory Board (XCAB) Conference Call Transcript
15.04.2015 Investor Update – April 2015
13.04.2015 EU Patent Granted – Further Extends Xanamem Protection
13.04.2015 Investor Presentation – April 2015
13.04.2015 Xanamem Clinical Advisory Board (XCAB) Conference Call

March

24.03.2015 Clinical Trial Update – Xanamem Drug for Alzheimer’s Dementia
17.03.2015 Powerhouse Alzheimer’s Advisory Board to Drive Xanamem Development
12.03.2015 Response to Price Query Letter
09.03.2015 Investor Presentation – March 2015

February

27.02.2015 Appendix 4D & Half Year Report
24.02.2015 First Participants Recruited for Second Phase I Xanamem Study
24.02.2015 Employee Share Plan Vesting Conditions Met
17.02.2015 Investor Presentation – February 2015
16.02.2015 Ethics Approval Granted for Second Phase I Study of Xanamem
16.02.2015 Investor Update – February 2015

January

29.01.2015 Appendix 4C: Quarterly
16.01.2015 Employee Share Plan Vesting Conditions Met
09.01.2015 US Investor Presentation – January 2015
07.01.2015 Response to ASX Query – Price Query

Subscribe to Our Newsletter

Actinogen 2017 ™
Contact Us